Abstract
Autologous Hematopoietic Stem Cell Transplantation (auto-HSCT) has become a therapeutic option for first-line consolidation in Acute Myeloid Leukemia (AML) patients with favorable and intermediate risk features. A total of 101 AML patients in first complete remission, who were not eligible for allogeneic HSCT, were randomized to receive intensive cytarabine-based chemotherapy or to undergo auto-HSCT. The probability of LFS was significantly better in auto-HSCT recipients compared to chemotherapy arm (43% vs 4.8%, p=0.008). At the end of 915 (30-4470) days of followup, the probability of overall survival was better in auto-HSCT group compared to chemotherapy, without statistical significance (79.2% vs 38.8%, p=0.054). Multivariate analysis revealed a significant predictive impact of cytogenetic risk status on OS (p=0.002, HR: 2.824, 95% CI: 1.445-5.521). Auto-HSCT is considered as an effective consolidation approach in favorable and intermadiate risk AML patients.
Highlights
Maintenance of remission is considered as a major concern in the primary treatment of Acute Myeloid Leukemia (AML) despite favorable remission rates after induction treatment
Correlation (LFS) in AML patients, distinct therapeutic analysis was performed using Pearson and Leukemia relapse was demonstrated in approaches for post-remission consolidation Spearman tests
Recipients, leukemia relapse was observed in 14 patients (45.2%) at median 225 (60-395)
Summary
A total of 101 AML patients in CR1 [median age: 47(19-79); male/female: 51/50], who were not eligible for allo-HSCT and did not have an HLA compatible donor, were randomized to receive intensive cytarabine-based chemotherapy or to undergo auto-HSCT after high dose cyclophosphamide and busulfan as conflict of interest. Ethics approval: The study was approved by the local ethical commitee of Gazi Medical School. Consent for publication: Consent has been obtained. Availability of data and materials: Available by authors. Conference Presentation: 7th International Congress on Leukemia, Lymphoma, Myeloma, İstanbul, Turkey, May 2019. ©Copyright: the Author(s), 2020 Licensee PAGEPress, Italy Hematology Reports 2020; 12:8380 conditioning regimen.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
